chartexchange

HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting

GlobeNewswire Inc. | Nov 6, 2026 9:15 AM EST

HCW11-018b induces/promotes tertiary lymphoid structure formation inside tumors

Read original article